What Coloverin SR Treats

Coloverin SR is a medication formulated to manage symptoms associated with functional gastrointestinal disorders. It belongs to a class of medicines known as antispasmodics, which work directly on the smooth muscles of the digestive tract.

Main Uses

The primary application of Coloverin SR is the symptomatic treatment of Irritable Bowel Syndrome (IBS) and similar conditions characterized by intestinal spasms. It is commonly used to address the following symptoms:

• Abdominal Pain and Cramping: Relieving the sharp or dull pain caused by involuntary muscle contractions in the gut.
• Bloating and Distension: Reducing the feeling of fullness and visible swelling in the abdominal area.
• Altered Bowel Habits: Assisting in the management of diarrhea or constipation when these are linked to intestinal spasms.
• Flatulence: Helping to alleviate discomfort caused by excess gas trapped in the digestive system.

Benefits and Mechanism

Coloverin SR utilizes a sustained-release (SR) mechanism, which allows the active ingredient to be released gradually into the system. This provides several clinical benefits:

• Targeted Action: The medication acts specifically on the muscle wall of the intestine to induce relaxation without affecting normal bowel movement or interfering with the autonomic nervous system.
• Extended Symptom Control: Due to its slow-release formulation, the medication provides a prolonged effect, helping to maintain comfort over a longer period compared to immediate-release versions.
• Reduction of Spasms: By preventing the hyper-reactivity of the intestinal muscles, it helps restore the natural rhythm of the digestive tract, leading to a reduction in the frequency and intensity of abdominal discomfort.

Who Can and Cannot Use Coloverin SR?

Regulatory authorities define the specific populations eligible for Coloverin SR (mebeverine hydrochloride) based on established safety and efficacy data. This medicine is primarily intended for use in adults aged 18 years and older.

---

Eligibility Restrictions

Category	Regulatory Status
Age Restriction	Not recommended for children and adolescents below 18 years due to insufficient data.
Pregnancy	Not recommended for use during pregnancy.
Breastfeeding	Should not be used by breastfeeding women.
Contraindications	Contraindicated in patients with known hypersensitivity (allergy) to the drug or its excipients.
Metabolic Disorders	Contraindicated in individuals with rare hereditary problems, such as galactose intolerance or glucose-galactose malabsorption.
Organ Function	Use with caution is advised for patients with advanced renal or hepatic impairment, as noted in some regulatory documents.

---

These constraints define the official eligibility profile and ensure the medicine is used only in populations where its use is documented as acceptable or established by governing health agencies.

Interactions with other medicines and products

The official interaction profile for Coloverin SR (mebeverine hydrochloride) is defined by the findings from regulatory-mandated studies and the absence of data for many common interaction types. The overall structure is characterized by a lack of formally documented restrictions concerning other medications.

Interaction Type	Official Regulatory Statement
Drug–Drug Interactions	No formal interaction studies have been performed with other medicinal products.
Metabolic Interactions	No specific metabolic (CYP enzyme) or drug transporter-mediated interactions are documented in regulatory labeling.
Contraindicated Combinations	The official prescribing information does not list any medicinal products that are formally prohibited for co-administration due to interaction risk.

The lack of documented studies means the regulatory profile contains no established rules for pharmacokinetic alterations or pharmacodynamic effects involving co-administered medicines. Consequently, there are no mandatory requirements for dose timing separation stated in the official prescribing information.

The single substance for which a formal interaction study result is documented is ethanol (alcohol). Regulatory authorities explicitly confirm the absence of any interaction between mebeverine hydrochloride and alcohol, based on findings from in vitro and in vivo studies. This finding forms the primary explicit piece of information available concerning external substance interactions. The interaction structure for Coloverin SR is thus focused on a general lack of available regulatory data concerning co-administered substances.

Direct Musculotropic Action and Ion Channel Modulation

Mebeverine primarily works by directly influencing the smooth muscle cells of the gastrointestinal (GI) tract. Its core mechanism involves modulating Voltage-operated Calcium ( Ca^2+) and Sodium ( Na^+) channels, which are essential regulators of muscle cell excitability and contraction. By interfering with the excessive influx of these ions across the cell membrane, the drug causes spasmolysis, resulting in the reduction of elevated smooth muscle tone and the modulation of GI smooth muscle contractile patterns.

Mechanistic Specificity and Sustained Effect Profile

The mechanism is characterized by its high degree of local specificity, exhibiting low affinity for non-target receptors, such as systemic muscarinic receptors. Furthermore, the Sustained-Release (SR) formulation is a mechanical feature that facilitates the pharmacological mechanism by continuously providing the drug to the muscle fibers. This prolonged and localized concentration allows for sustained modulation of muscle excitability to be maintained over an extended period.

How to Use Coloverin SR

Coloverin SR (mebeverine hydrochloride) is a medication formulated for oral use only as a 200 mg modified-release capsule. The general principles for administration focus on ensuring the sustained-release mechanism is maintained and aligning the timing with meals.

---

Standard Administration Guidelines

Feature	Official Use Principle
Route & Form	Oral; 200 mg modified-release capsule.
Adult Dosing	One capsule (200 mg) per dose.
Frequency	Twice daily (B.I.D.), typically morning and evening.
Intake Condition	Taken approximately 20 minutes before a meal.

---

Procedural Instructions

The modified-release capsule must be swallowed whole with a sufficient amount of water (e.g., 100 ml); it must not be chewed or crushed. This specific instruction is necessary to preserve the intended slow release of the active ingredient.

Duration and Special Populations

Treatment duration is not limited and may continue as needed for symptomatic relief. Guidance suggests that the dose may be gradually reduced once symptoms have been controlled for several weeks. No dosage adjustment is generally required for older adults or patients with kidney or liver impairment. However, use is not recommended for children and adolescents under 18 years of age due to insufficient safety and efficacy data.

In the event of a missed dose, the patient should not take a double dose to compensate; the regular dosing schedule should simply be resumed with the next planned dose.

Coloverin SR: Recent Clinical Evidence

---

Evidence for Symptomatic Management of Irritable Bowel Syndrome (IBS)

This section summarizes the core clinical evidence base for Coloverin SR, describing the types of Randomized Controlled Trials (RCTs), Systematic Reviews, and Meta-analyses that research examined in studies examining outcomes related to the primary symptoms of IBS. Coloverin SR was studied for conditions characterized by fluctuating or episodic manifestations, such as Irritable Bowel Syndrome and related functional bowel disorders. Short-term RCTs, which compare the drug to an inactive placebo, were studied in adult populations diagnosed with IBS. Findings describe patterns observed in the studies regarding the proportion of participants reporting improvement in global symptoms and abdominal pain, which is the key area used in research exploring patient-reported outcomes.

Outcomes Studied in Clinical Trials

The trials used in research exploring how symptoms change over time focused heavily on outcomes related to physical discomfort, primarily abdominal pain and cramping. Studies explored how symptoms evolved in the observed populations, with endpoints including a patient’s global assessment of relief and the severity of outcomes related to systemic or functional imbalance, such as abdominal distension and bloating. Research also examined outcomes related to abnormal bowel habits, including stool frequency and consistency.

---

Comparison of Findings to Placebo and Other Treatments

This part outlines the structure of comparative studies that have been conducted, including how data were gathered where Coloverin SR was studied alongside other treatments and when it was evaluated in comparisons to other available antispasmodic agents. Reviews indicate that for the primary outcome of global symptom improvement, concerns related to consistency were reported when compared with placebo in some large-scale scientific reviews.

---

Long-Term Studies and Follow-up Duration

The follow-up durations for many randomized trials were limited, ranging typically from four to sixteen weeks. There is limited information for long-term outcomes that persist beyond six months, and long-term effects are not fully established regarding the durability of findings.

---

Scientific Uncertainty and Research Gaps

This concluding section synthesizes the main limitations documented in regulatory and peer-reviewed summaries, clarifying the areas where findings were mixed, where research is still developing, and where data remain insufficient. Certainty remains low concerning the overall consistency of results when data from all short-term RCTs were evaluated in meta-analyses. Furthermore, subgroup findings are uncertain regarding how different IBS subtypes may have been explored across the entire research landscape.

Key Studies & References

1. The Efficacy of Mebeverine in the Treatment of Irritable Bowel Syndrome—A Systematic Review (2022)
2. Mebeverine and the Influence of Labeling in Adolescents With Irritable Bowel Syndrome or Functional Abdominal Pain Not Otherwise Specified (2019)
3. Irritable bowel syndrome in adults: diagnosis and management (NICE Guideline CG61)
4. Public Assessment Report Scientific discussion Mebeverine Aristo 200 mg modified release capsules (NL Regulatory Document)

Common questions about Coloverin SR (FAQ)

---

Q: Is Coloverin SR known to cause weight gain or weight loss?

Official regulatory information does not indicate that Coloverin SR is known to cause weight gain or weight loss. Any weight fluctuations or changes in appetite are typically not listed among the documented side effects of this medication. Such changes are typically reported to a healthcare professional.

---

Q: Can Coloverin SR affect sleep patterns?

Some official regulatory documents list insomnia, or difficulty sleeping, as a possible adverse effect that has been reported by users. The frequency of such sleep-related effects is generally categorized in official documents as 'Not Known.' This indicates that while it is possible, it is not established as a common reaction.

---

Q: Are there any foods or drinks that should be completely avoided when taking Coloverin SR?

Official regulatory documents do not specify any particular foods or non-alcoholic drinks that must be completely avoided when using Coloverin SR. This information is consistent with the drug's official interaction profile.

---

Q: Does Coloverin SR make you feel drowsy or tired?

Tiredness (malaise) is listed in some regulatory documents as a reported adverse effect. Official guidance indicates that mebeverine is not likely to affect the ability to drive or use machinery for most people. However, Official guidance describes that the ability to drive or operate machinery may be affected if dizziness or significant tiredness is experienced.

---

Q: Is it common to have stomach upset when first starting Coloverin SR?

According to patient information, general gastrointestinal side effects such as indigestion or heartburn may occur when first starting this medicine. Patient information describes these effects as mild and temporary, which may lessen as the body adjusts to the medication.

---

Q: Can Coloverin SR affect blood pressure or heart rate?

Regulatory safety information includes reports that a decreased heart rate (bradycardia) or palpitations have occurred in rare instances. These are generally listed as adverse effects with a frequency of 'Not Known.' Any concerning cardiovascular symptoms are typically reported to a healthcare professional.

---

Q: Can Coloverin SR affect mood or cause anxiety?

The main focus of the regulatory safety profile is on physical symptoms and allergic reactions. However, some reporting data related to the use of mebeverine have included mentions of depression as a possible side effect. Changes in mood are typically reported to a healthcare professional.

---

Q: Is it true that Coloverin SR is sometimes used for conditions other than its main approved use?

The approved, primary indication for Coloverin SR is for the symptomatic relief of Irritable Bowel Syndrome (IBS) and related functional bowel disorders. Official guidelines describe the medicine’s use for this approved condition only.

---

Q: Can taking Coloverin SR affect fertility?

Studies concerning reproductive health in animals show no evidence that the drug affects fertility. Currently, there is no clinical data specifically available on human male or female fertility in the official product information.

---

Q: What is the maximum amount of time Coloverin SR can stay in the system?

The sustained-release (SR) design of Coloverin SR is intended to prolong the effect by extending the elimination half-life compared to plain tablets. The medicine is almost completely metabolized in the body, and the resulting components are mainly excreted through the urine.

---

Q: Is Coloverin SR widely recognized by medical professionals for this condition?

Coloverin SR (mebeverine) is described in official therapeutic guidelines as an established antispasmodic agent. It is widely recognized and indicated for the symptomatic treatment of Irritable Bowel Syndrome (IBS) and related functional bowel disorders in adults.

---

Q: Is there a generic version of Coloverin SR available?

Yes, the active ingredient in Coloverin SR, which is mebeverine hydrochloride, is a generic drug. This active ingredient is available internationally under various brand names as well as generic formulations.

---

Q: What steps are outlined in official documents if a side effect occurs while on Coloverin SR?

Official patient information describes that in the event of serious allergic reactions, such as difficulty breathing or swelling of the face, the medicine's use is often discontinued and immediate medical attention is sought. For other less serious or bothersome effects, reporting the reaction to a doctor or pharmacist is the documented procedure.

---

Q: Does Coloverin SR contain gluten or common allergens?

The product is restricted for individuals with known hypersensitivity to the drug or its non-active components (excipients). Official patient information does not specify gluten in its contraindications. Users who have concerns about non-active ingredients are typically referred to their prescribing information.

---

Q: What do official guidelines say about driving while using Coloverin SR?

Official regulatory documents state that the medication has no or negligible influence on the ability to drive or use machines. However, Official guidance describes that the ability to drive or operate machinery may be affected if dizziness or tiredness is experienced.

---

Q: Is Coloverin SR an opioid or does it contain controlled substances?

Coloverin SR (mebeverine) is classified as a musculotropic antispasmodic agent that acts directly on the smooth muscle of the gut. It is not classified as an opioid and does not contain any controlled substances in major regulatory jurisdictions.

Official Storage and Disposal Requirements

Coloverin SR must be stored strictly according to regulatory mandates to ensure stability and effectiveness. The product requires storage at a temperature below 25°C; it is prohibited to refrigerate or freeze the capsules.

---

Storage Conditions

Requirement	Status
Temperature	Store below 25 °C. Do not refrigerate or freeze.
Protection	Protect from light and store in a dry place.
Packaging	Keep in the original blister and outer carton.
Child Safety	Keep out of the sight and reach of children.

---

Disposal Instructions

Disposal must adhere to environmental guidelines. Do not dispose of unused or expired Coloverin SR via wastewater or household waste. The proper procedure is to take the unused medicine to a pharmacist or designated collection point, following local requirements.